Navigation Links
Data From Clinical Study of bioTheranostics Molecular Diagnostic Test Presented at American Society of Clinical Oncology Annual Meeting
Date:6/1/2009

- THEROS CancerTYPE ID(R) predicts cancer origin with 75 percent accuracy in patients whose primary cancer was 'unknown' using traditional diagnostics -

SAN DIEGO, June 1 /PRNewswire/ -- bioTheranostics, a bioMerieux company that discovers, develops and commercializes new molecular diagnostic tests in oncology, announced that a recent study demonstrated the company's THEROS CancerTYPE ID(R) molecular diagnostic test predicted cancer origin with 75 percent accuracy in patients whose primary cancer was initially "unknown" using traditional diagnostics. Findings were presented today at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fl.

Three to five percent of all cancer patients(1) (the equivalent of 45,000-75,000 new patients each year in the United States alone) receive a diagnosis of cancer of unknown primary origin, or CUP, meaning their cancer has spread to multiple locations and the site where the cancer started can not be determined. Given that the origin of a cancer significantly impacts physicians' therapeutic decisions as well as patients' prognoses, the inability to diagnose patients' primary cancers makes it more difficult for physicians to determine optimal treatment plans. Molecular diagnostic tests such as the THEROS CancerTYPE ID have demonstrated the ability to predict the origin of tumors with a higher success rate than traditional diagnostic tests, thereby helping to reduce the number of cancers that remain "unknown".

The blinded study involved 28 patients who had an unknown primary cancer that was subsequently identified during their lives. Researchers assessed tissue from these patients' initial biopsies, determining that 20 of them were appropriate for testing with the THEROS CancerTYPE ID (eight were excluded given insufficient tumor tissue or poorly preserved RNA). Without accessing other clinical or pathological data for these patients, the team then co
'/>"/>

SOURCE bioTheranostics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Calif., July 29, 2014 Amgen (NASDAQ: ... second quarter of 2014. Key results include: , ... 8 percent product sales growth driven by strong performance ... ® (carfilzomib), Prolia ® (denosumab) and XGEVA ... percent to $2.37, driven by higher revenues and a ...
(Date:7/29/2014)... 29, 2014  Express Scripts Holding Company (Nasdaq: ... attributable to Express Scripts stockholders of $515.2 million, or ... as detailed in Table 4, was $1.23 for the ... positioned to serve our clients with scale, alignment and innovative ... the health outcomes of our members," stated George Paz, chairman ...
(Date:7/29/2014)... SAN DIEGO, July 29, 2014  Sequenom, Inc. (NASDAQ: ... innovative genetic analysis solutions, today reported total revenues of ... increase of 62% compared to revenues of $24.5 million ... The Bioscience business segment, which was sold on May ... operation and consequently its results have been excluded from ...
Breaking Medicine Technology:Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 2Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 3Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 4Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 5Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 6Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 7Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 8Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 9Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 10Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 11Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 12Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 13Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 14Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 15Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 16Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 17Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 18Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 19Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 20Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 21Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 22Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 23Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 24Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 8Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 9Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 10Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 11Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 12
(Date:7/29/2014)... HealthDay Reporter TUESDAY, July 29, ... a task, various brain connections fire up. But scans ... autism, according to a small new study. Moreover, ... less of this "brain flexibility," the researchers found. ... children with autism are faced with new situations," said ...
(Date:7/29/2014)... helps keep pool water clean, but it can also ... say. Pool swimmers can also develop red, ... Sampson Davis, an emergency room physician at Meadowlands Hospital ... understand why this happens, Davis said. Swimming in ... the eye that helps protect against infection. And chlorine ...
(Date:7/29/2014)... the bite of a brown recluse spider is poisonous, ... expert notes. It,s still important to recognize the ... recluse spider bite, warned Dr. Donna Seger, medical director ... dangerous bites are on the rise. "As physicians, ... [bite] has classic characteristics, but if physicians are not ...
(Date:7/29/2014)... CA (PRWEB) July 29, 2014 As the ... working with its partners to both purchase critical emergency supplies ... the US to Liberia. These supplies will contain materials used ... the most heavily populated areas of the country. , ... involved in the response to the Ebola outbreak in the ...
(Date:7/29/2014)... CA (PRWEB) July 29, 2014 According ... website of Time Magazine titled “From Kim’s Butt to ... Kim Kardashian’s butt is the celebrity feature most ... their features include Beyoncé’s butt, Jennifer Lawrence’s ... This information is based on data collected by an ...
Breaking Medicine News(10 mins):Health News:Less Flexibility Seen in Brain Wiring of Kids With Autism: Study 2Health News:Less Flexibility Seen in Brain Wiring of Kids With Autism: Study 3Health News:Protect Your Eyes When Hitting the Pool 2Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2Health News:PCI Responds to Ebola Outbreak in Liberia with Supplies, Awareness Campaigns 2Health News:PCI Responds to Ebola Outbreak in Liberia with Supplies, Awareness Campaigns 3Health News:Celebrity Plastic Surgery: Kim Kardashian’s Butt Tops the List of Celebrity Plastic Surgery Requests 2
... , March 15 The Board of Directors of Healthcare Trust of America, Inc. ("HTA"), ... June 2010 .  These distributions will be calculated based on the stockholders of record each day ... $10.00 . , ... ...
... The nation,s theater owners were asked today by the head of a major Hollywood studio to have healthier snacks at their concession stands in addition to their traditional ... ... ... ...
... people who suffer a break up to eight times more likely ... Older men and women who break a hip are five to ... after the fracture, a new study by Belgian researchers has found. ... substantially during the first two years after the break, it never ...
... from Boston University School of Medicine (BUSM) believe teaching ... into internal medicine residency training and can be done ... on-line in BioMedCentral Medical Education , represent a ... residents. Unhealthy substance use can be serious and ...
... , CHICAGO , March 15 ... submitted its detailed responses on two major regulations that ... and Reinvestment Act of 2009 (ARRA).  One comment addressed ... (ONC) Interim Final Rule (IFR) on EHR certification criteria ...
... The effect might be strongest after menopause, mouse study ... have believed that testosterone and estrogen play a major ... in mice suggests that female sex chromosomes could also ... the study, researchers genetically engineered male mice to have ...
Cached Medicine News:Health News:Healthcare Trust of America Board of Directors Declares Distributions 2Health News:Healthcare Trust of America Board of Directors Declares Distributions 3Health News:Movie Theaters Asked to Offer Healthier Snacks at Concession Stands 2Health News:Movie Theaters Asked to Offer Healthier Snacks at Concession Stands 3Health News:Movie Theaters Asked to Offer Healthier Snacks at Concession Stands 4Health News:Movie Theaters Asked to Offer Healthier Snacks at Concession Stands 5Health News:Movie Theaters Asked to Offer Healthier Snacks at Concession Stands 6Health News:Risk of Death Persists After a Hip Fracture 2Health News:Risk of Death Persists After a Hip Fracture 3Health News:Researchers recommend curriculum on unhealthy substance use 2Health News:HIMSS Electronic Health Record Association Responds to Proposed Meaningful Use and Certification Rules 2Health News:HIMSS Electronic Health Record Association Responds to Proposed Meaningful Use and Certification Rules 3Health News:HIMSS Electronic Health Record Association Responds to Proposed Meaningful Use and Certification Rules 4Health News:HIMSS Electronic Health Record Association Responds to Proposed Meaningful Use and Certification Rules 5Health News:Women's Chromosomes May Affect Blood Pressure 2
Silicone ICD lead...
The Livewire steerable electrophysiology catheter is uniquely designed with an ergonomic handle and patented steering mechanism to provide smooth, precise catheter tip movement, even during lengthy e...
... The SOLX DeepLight Glaucoma ... invasive, yet highly effective glaucoma ... our DeepLight Gold Micro-Shunt (GMS) ... Laser that help use the ...
The Verity ADx pacemaker family, which includes the world's longest lasting single- and dual-chamber pacemakers, provides clinicians with a variety of feature options and header configurations to mee...
Medicine Products: